|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that expression of the met/HGF receptor may be involved in the onset and progression of renal cell carcinomas.
|
8682590 |
1996 |
|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that altered expression of the HGF/SF receptor, c-met, may be involved in the pathogenesis of certain renal cell carcinomas.
|
9258068 |
1997 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the tyrosine-kinase domain of the MET proto-oncogene were found in patients suffering from the hereditary predisposition to develop multiple papillary renal-cell carcinomas (hereditary PRCC, HPRCC).
|
10417759 |
1999 |
|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined the gene expression of HGF and MET in 27 primary RCC tumors by quantitative competitive RT-PCR.
|
10022739 |
1999 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Wilms' tumour and the WT-1 gene, renal cell carcinoma and the c-met receptor tyrosine kinase gene), some to be caused by mutations in genes expressed during normal development (e.g. renal cell carcinoma and the TSC-2 gene, renal cell carcinoma of the clear cell variety and the VHL gene).
|
10535327 |
1999 |
|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that expression of the MET proto-oncogene above a critical threshold is required for the maintenance of the tumorigenic phenotype of at least some papillary renal cell carcinomas, but does not further increase during tumour progression.
|
10698493 |
2000 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, mutations of the MET oncogene could not be found in the seven ESRD/ACDK-associated papillary RCCs examined.
|
12378530 |
2002 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, these results strongly suggest that the expression of HGF/SF and Met protein is closely associated with the genetic alterations of VHL and HGF/SF in primary RCCs.
|
12076276 |
2002 |
|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined the role of increased expression of HGFR kinase in in vivo growth of renal carcinoma.
|
12646256 |
2003 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although hidden genetic changes have been found in some trisomies, for example, mutations in KIT in acute myelocytic leukemia (AML) with +4 and in MET in hereditary papillary kidney carcinoma with trisomy 7, none associated with +8 have so far been discovered.
|
12550762 |
2003 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, all hereditary and sporadic papillary RCCs with MET proto-oncogene show type 1 histological features.
|
12647800 |
2003 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies of the hereditary form of renal cell carcinoma (RCC) associated with hereditary papillary renal carcinoma (HPRC) determined that the c-Met proto-oncogene on chromosome 7 is the gene for HPRC and for a number of sporadic papillary RCCs.
|
15448018 |
2004 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Hereditary papillary renal carcinoma type I.
|
15579033 |
2004 |
|
Renal Cell Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MET was up-regulated in most cases of RCC.
|
14713848 |
2004 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased cell motility associated with HAI-2/SPINT2 inactivation was abrogated by treatment with extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phospholipase C-gamma inhibitors, but not by an inhibitor of atypical protein kinase C. These findings are consistent with frequent epigenetic inactivation of HAI-2/SPINT2, causing loss of RCC tumor suppressor activity and implicate abnormalities of the MET pathway in clear cell and papillary sporadic RCC.
|
15930277 |
2005 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phosphorylated HGFR/c-Met may be important in the tumor progression of RCC.
|
16914575 |
2006 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
|
18636147 |
2008 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations of MET also have been identified in a subset of tumors from patients with sporadic type 1 papillary renal cell carcinoma (RCC).
|
19402075 |
2009 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the MET and fumarate hydratase (FH) genes lead to the development of type 1 and type 2 papillary RCCs, respectively, and such mutations of either the TSC1 or TSC2 gene increase the risk of RCC.
|
21228928 |
2010 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET is the gene for the hereditary form of type 1 papillary renal carcinoma and is mutated in a subset of sporadic type 1 papillary kidney cancers.
|
20059341 |
2010 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma.
|
23219378 |
2013 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC.
|
24000165 |
2013 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC.
|
23895657 |
2013 |
|
Renal Cell Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dysregulation of c-Met and hepatocyte growth factor have been observed in both clear cell and non-clear cell renal cell carcinomas (RCCs), although only papillary RCCs harbor activating mutations in the MET gene.
|
23867513 |
2014 |
|
Renal Cell Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
If these results are further validated in a similar population, they could be incorporated into future prognostic instruments, potentially aiding the design of adjuvant clinical trials of MET inhibitors and management of renal-cell carcinoma.
|
24767687 |
2014 |